ArticleJapanese journal of clinical oncology2017

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.

Junji Furuse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.